Comparison of the efficacy and safety of paclitaxel-eluting coroflex please stents and paclitaxel-eluting stents in patients with coronary artery disease: A randomized PIPA trial
Catheterization and Cardiovascular Interventions, 04/20/2012
Kim HS et al. – The Coroflex Please stent resulted in similar angiographic and clinical outcomes as the Taxus Liberte stent in patients with coronary artery lesions.
- Authors randomly assigned 319 patients to receive Coroflex Please stents (159 patients; 198 lesions) or Taxus Liberte stents (160 patients; 232 lesions).
- The primary end point was angiographic in–segment late luminal loss at 9 months.
- Most baseline clinical and angiographic characteristics were similar between these two groups.
- The Coroflex Please and Taxus Liberte stents showed similar in–segment late loss (0.40 ± 0.53 mm vs. 0.39 ± 0.52 mm, P = 0.98) and rates of in–segment binary restenosis (22.2% vs. 18.8%, P = 0.48) at 9 months.
- After clinical follow–up for 12 months, the two groups had similar rates of death (1.3% vs. 1.3%, P > 0.99), myocardial infarction (3.8% vs. 7.5%, P = 0.22), stent thrombosis (2.5% vs. 1.9%, P = 0.72), and target–lesion revascularization (7.5% vs. 7.5%, P = 0.99).